Obsessive-compulsive disorder is a type of anxiety disorder in which person has compulsive behaviour and uncontrollable recurring thoughts. The signs and symptoms of obsessive-compulsive disorders are obsession and compulsion. Obsession involves aggressive and unforbidden thoughts related to sex, religion and harm, fear of germs, and having things in symmetrical order. Compulsion includes excessive cleaning, ordering things in a precise way, and repeatedly checking on things. According to the researchers, the brain circuits may not work properly. The risk factors associated with obsessive-compulsive disorder include genetic, brain structure and functioning, and surroundings. Obsessive-compulsive disorders can be treated by serotonin reuptake inhibitor and selective serotonin reuptake inhibitor. New York State Psychiatric Institute is in the process of developing Ketamine as a N-methyl-D-aspartate blocker for the treatment of obsessive-compulsive disorders. University of Minnesota is in the process of developing sertraline as a serotonin reuptake inhibitor for the treatment of obsessive-compulsive disorders. Some of the companies/universities having the pipeline of obsessive-compulsive disorder include New York State Psychiatric Institute, Stanford University, and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.